Results 201 to 210 of about 53,197 (261)
, 2005 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Challenge of Surrogate Endpoints
Southern Medical Journal, 2012Surrogate endpoints are biomarkers that are intended to substitute for clinical endpoints. They have been used to find novel therapeutic targets, improve the statistical power and shorten the duration of clinical trials, and control the cost of conducting research studies.
James L, Furgerson +2 more
openaire +2 more sources
True endpoint reduction by surrogate endpoints
Communications in Statistics - Simulation and Computation, 2016ABSTRACTThe use of surrogate endpoint, which is becoming widely popular now a days, was introduced in medical research to reduce the time of experiment required for the approval of a drug. Through cost cutting and time saving, the surrogate endpoints can bring profit to the medicine producers. We obtain the expression for the reduction of true samples,
Buddhananda Banerjee, Atanu Biswas
openaire +2 more sources
The Evaluation of Multiple Surrogate Endpoints
Biometrics, 2001Summary.Surrogate endpoints are desirable because they typically result in smaller, faster efficacy studies compared with the ones using the clinical endpoints. Research on surrogate endpoints has received substantial attention lately, but most investigations have focused on the validity of using a single biomarker as a surrogate.
Xu, Jane, Zeger, Scott L.
openaire +2 more sources
Evaluating surrogate endpoints
Controlled Clinical Trials, 2002The validation of surrogate endpoints has been studied by Prentice, who presented a definition as well as a set of criteria that are equivalent if the surrogate and true endpoints are binary. Freedman et al. supplemented these criteria with the so-called proportion explained.
openaire +2 more sources
2023
In Chapter 3, I utilize publicly available datasets of gene expression and DNA methylation in sarcomas to interrogate PRC2-dependent mechanisms of epigenetic crosstalk. I have shown that loss of PRC2 correlates with a global hypermethylation profile, tumor microenvironment changes, and patient outcome.
openaire +1 more source
In Chapter 3, I utilize publicly available datasets of gene expression and DNA methylation in sarcomas to interrogate PRC2-dependent mechanisms of epigenetic crosstalk. I have shown that loss of PRC2 correlates with a global hypermethylation profile, tumor microenvironment changes, and patient outcome.
openaire +1 more source
Change in albuminuria as a surrogate endpoint
Current Opinion in Nephrology and Hypertension, 2019Chronic kidney disease is a global health problem with few effective therapies available that slow the progression to end-stage renal disease. The established clinical endpoints for renal trials; doubling of serum creatinine or end-stage renal disease, are late manifestations of CKD.
Simke W, Waijer +2 more
openaire +2 more sources
Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease.
Nutrition reviews, 2008This article reviews surrogate endpoints and emerging biomarkers that were discussed at the annual "Cardiovascular Biomarkers and Surrogate Endpoints" symposium cosponsored by the US Food and Drug Administration (FDA) and the Montreal Heart Institute.
Crystal M, Rasnake +2 more
openaire +3 more sources
Surrogate Endpoints in Suicide Research
Suicide and Life-Threatening Behavior, 2010Surrogate endpoints frequently substitute for rare outcomes in research. The ability to learn about completed suicides by investigating more readily available and proximate outcomes, such as suicide attempts, has obvious appeal. However, concerns with surrogates from the statistical science perspective exist, and mounting evidence from psychometric ...
Hal S, Wortzel +4 more
openaire +2 more sources